Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Alzheimer’s Drugs Industry?

In recent times, there has been robust growth in the Alzheimer’s drugs market size. It is projected to escalate from $9.33 billion in 2024 to $10.09 billion in 2025, with an 8.1% compound annual growth rate (CAGR). The soaring numbers in Alzheimer’s disease instances, R&D investments, better comprehension of disease mechanisms, global health campaigns, public consciousness, and education have all contributed to the growth during the historic period.

The market size for Alzheimer’s drugs is predicted to observe substantial advancement in the coming years, potentially increasing to $14.16 billion by 2029 with an 8.8% compound annual growth rate (CAGR). The augmentation in the outlook period is connected with precision medicine methodologies, emphasis on disease alteration, identification and validation of biomarkers, patient-focused drug evolution, and concentration on non-pharmacological interventions. Key trends in the projection period encompass diverse healing methods, virtual health remedies, regenerative medicine, progression in diagnostic tools, the use of artificial intelligence (AI) in drug detection, and cooperative partnerships.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

What Forces Are Driving The Growth Of The Alzheimer’s Drugs Industry?

The growth of the Alzheimer’s drugs market is anticipated to be fuelled by the increasing occurrence of Alzheimer’s disease. Alzheimer’s disease, a neurologic condition, progressively deteriorates, resulting in brain shrinkage and cell death. Treatment for Alzheimer’s, commonly with drugs, are primarily used to address memory loss, cognitive issues and challenges with day-to-day living. Such treatments aim to enhance the standard of living and aid in maintaining independence. For instance, a report by the Alzheimer’s Association in May 2024— a US-based nonprofit organization devoted to Alzheimer’s care, support, and research— revealed that the population of Americans 65 years or older diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to approximately 6.9 million in 2024. Hence, the growth of the Alzheimer’s drugs market can be attributed to the rising occurrence of Alzheimer’s disease.

What Is The Overview Of Market Segmentation In The Alzheimer’s Drugs Industry?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Subsegments:

1) By Donepezil: Oral Tablets, Oral Solution

2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches

3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules

4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules

What Future Market Trends Are Projected For The Alzheimer’s Drugs Industry?

Significant businesses in the Alzheimer’s drugs market, such as Eli Lilly and Company, are innovating new medicines like amyloid plaque-targeting therapy to enhance treatment procedures and ameliorate patient results. Amyloid plaque-targeting therapy is a treatment technique that aims to minimize or inhibit the build-up of amyloid-beta plaques in the brain, which is a common characteristic of Alzheimer’s disease. In June 2024, Eli Lilly and Company received approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), the US federal agency responsible for public health protection. Kisunla (donanemab-azbt) is the debut and singular amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease that aids in eliminating abundant amyloid plaques in the brain, which correlates with cognitive deterioration in Alzheimer’s sufferers. Kisunla is dispensed through intravenous infusion every month. The primary dosage involves 700 mg for the first three doses, followed by 1400 mg for subsequent doses. Kisunla is specifically recommended for adults in the early dementia stages of Alzheimer’s disease, especially if they have a confirmed amyloid pathology.

Who Are The Primary Players Operating Across The Global Alzheimer’s Drugs Market?

Major companies operating in the alzheimer’s drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Which Region Offers The Most Growth Potential For The Alzheimer’s Drugs Market Through 2029?

North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model